Agency also started to allow exclusive cultivation for export; standards were published on Wednesday (May 13)
The (National Health Surveillance Agency) published new rules for cannabis-based products on Wednesday (May 13, 2026). The determinations relax the requirements for prescribing products with a low THC (tetrahydrocannabinol) content.
The new rule allows the prescription, with a Special Control Prescription —the simplest prescription model used for other controlled medications—, of products with a THC concentration equal to or less than 0.2%.
According to Anvisa, the objective is to reduce bureaucracy and facilitate access to products for doctors and patients.
Cultivation of the species is also now permitted Cannabis sativa L. with a THC content of up to 0.3%, but exclusively for export.
According to the standard, companies interested in cultivating must prove export estimates through contracts or documents of intention to purchase, sell and distribute.
The decision comes in the context of the regulation of medical cannabis made by the .
The Court defined criteria for low-THC cultivation.
The medical cannabis market has grown in recent years in Brazil, driven by the increase in import authorizations and the entry of products regulated by Anvisa.
